HIVE Is Down 89% Over 2,000 Days. What History Says Now

HIVE Is Down 89% Over 1,995 Days. What History Says

HIVE Digital Technologies Ltd. (HIVE) is now down 89% from its all-time high as of August 24, 2026, having spent approximately 2,000 days in this drawdown. The Drawdown Severity Score™ has improved to 11.5, representing a slight shift within the red zone. In 2 comparable prior recoveries of this depth, the stock moved to its next recovery phase within an average of 1,806 days, indicating that deep corrections for this asset require extensive periods to resolve.

Current Drawdown Severity and the Red Zone

The current price of $2.86 is a long way from the all-time high of $26.85. This gap translates to a current drawdown of -89.3% as of August 24, 2026. This prolonged decline has lasted 1,995 days, keeping the asset within our most critical risk category.

Our proprietary Drawdown Severity Score™ stands at 11.5 as of August 24, 2026, which places the stock in the Extreme, red zone. The previous zone was also red. While we observe some minor price stabilization at the $2.86 level, the severity score indicates that the stock has not yet established a meaningful upward trajectory to escape this high-risk classification.

The red zone represents drawdowns that are mathematically severe relative to the asset's typical trading behavior. When a stock enters this zone, historical volatility often remains elevated, and recovery timelines become highly unpredictable. Our data shows that HIVE has spent a considerable portion of its recent history navigating these extreme levels.

Historical Timeline of HIVE's Drawdowns

HIVE has a history of highly volatile market cycles, which is common for companies operating in the digital asset infrastructure space. Our database tracks a total of 5 historical drawdown events for this stock. Across all tracked events, the average max drawdown is -46.4%, with an average drawdown duration of 728 days.

The current drawdown of -89.3% is far more severe than the historical average. It has also lasted 1,995 days, which is more than double the average duration of 728 days. This indicates that the current cycle is an outlier in terms of both depth and duration.

Valuation Versus Its Own Record

To understand how the market is pricing the stock during this recovery phase, we examine its valuation multiples relative to its own history. As of the valuation snapshot on 2026-08-22, the Price-to-Sales ratio (P/S) for HIVE sits at 2.5. This ratio is in the 38th percentile of its own daily P/S record since 2014-08-12, placing it within its typical historical range, slightly below its historical median of 3.0.

Conversely, the EV-to-EBITDA ratio (EV/EBITDA) stands at 168.4 as of 2026-08-22, which is in the 97th percentile of its own daily EV/EBITDA record since 2013-04-01. This is historically high versus its own historical median of 4.6.

This divergence highlights a crucial risk context: while the price drawdown of -89.3% has brought the revenue-based multiple (P/S) down to its typical historical range, the earnings-based multiple (EV/EBITDA) remains exceptionally elevated compared to the company's past performance. We present these figures strictly as historical context to help investors assess how the current valuation aligns with past cycles: they are not a recommendation to buy or sell the asset. Furthermore, given that the historical comparison relies on a small sample size of only 2 prior comparable deep drawdown events, these averages should be interpreted with caution.

Historical Comparison of Deep Drawdown Events

To find more accurate historical precedents, we look at comparable drops where the stock fell by 80% or more. Our data shows this has occurred 2 times in the stock's history. The average duration of these comparable drops is 1,806 days.

The current drawdown has now lasted 1,995 days, surpassing the historical average duration for these deep corrections. This extended duration suggests that the stock is in uncharted territory, struggling to find the catalysts needed to drive a sustained recovery.

A standard correction of -46.4% typically represents a cyclical downturn that resolves within a couple of years. An extreme drawdown exceeding 80% represents a structural repricing of the asset. In HIVE's history, these 80%+ drops have required an average of 1,806 days to recover, showing that once investor confidence is impaired to this degree, rebuilding the market capitalization is a multi-year process.

Fundamental Drivers and Recent News Context

Several fundamental factors explain why the stock remains under intense pressure. According to Yahoo Finance, HIVE reported a Q1 loss and lagged revenue estimates in its recent earnings release, highlighting operational headwinds. This disappointing performance was also reported by Quiver Quantitative, which noted that the stock fell following its Q1 2027 earnings announcement.

In response to these financial results, analysts have adjusted their expectations. According to StocksToTrade, HIVE stock adjusted as analysts cut price targets, reflecting a more cautious outlook on the company's near-term growth prospects. Additionally, an analysis by kalkine.ca reported that the stock remains under pressure, with bearish momentum raising correction and valuation concerns.

These headlines align closely with our valuation data. The elevated EV/EBITDA ratio of 168.4, sitting in the 97th percentile as of 2026-08-22, suggests that operating earnings have compressed significantly faster than the enterprise value. This mismatch explains why analysts remain cautious despite the steep decline in the stock price.

Historical Recovery Timelines and Risk Framing

When evaluating historical recoveries, we must consider the structural shifts in the company's business model. HIVE has transitioned from a pure-play cryptocurrency miner to a digital technology firm focusing on high-performance computing (HPC) and artificial intelligence infrastructure. This transition requires significant capital expenditure, which can depress short-term earnings and inflate valuation multiples like EV/EBITDA.

High-performance computing transitions require substantial infrastructure investments, such as purchasing advanced graphics processing units (GPUs) and securing high-capacity power contracts. These investments increase capital expenditure, which directly impacts EBITDA. When revenue lags estimates, as reported by Yahoo Finance, the high fixed costs of operating data centers can lead to significant net losses.

To recover to its all-time high of $26.85 from the current price of $2.86, the stock must gain approximately 839%. This massive required return highlights why these deep drawdowns take so long to resolve. Historically, our data shows that the average duration of comparable drops is 1,806 days, but the current event has already run for 1,995 days. This makes the current drawdown the longest in HIVE's history, signaling that the structural challenges facing the company are more persistent than in previous cycles.

Key Metrics to Watch Moving Forward

As we monitor HIVE's path forward, several key thresholds will help determine if the stock is beginning a genuine recovery. First, watch the Drawdown Severity Score™. A decline in this score below 10.0 would signal that the stock is finally transitioning out of the Extreme, red zone and into a lower risk category.

Second, monitor the valuation multiples in future updates. Will the EV/EBITDA ratio contract from its 97th percentile toward its historical median of 4.6? A contraction driven by rising EBITDA rather than falling share prices would be a positive fundamental indicator.

Conversely, if the Price-to-Sales ratio drops below its 38th percentile of 2.5, it may indicate that revenue growth is slowing, which could trigger further downward pressure. We will continue to track these proprietary metrics to provide data-driven updates on HIVE's drawdown status.